MC
PFE icon

Moors & Cabot’s Pfizer PFE Stock Holding History

Moors & Cabot’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100
Closed -$2K – 892
2022
Q1 		$2K Buy
+100
New +$5.19K ﹤0.01% 893

Other funds holding PFE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Moors & Cabot's PFE Position: Q1 2026 in Review

Moors & Cabot increased its Pfizer (PFE) stake by 4.4% in Q1 2026, buying an estimated $329K and bringing the position to 294,767 shares worth $8.28M. The position accounts for 0.35% of the portfolio, ranked #53.

Moors & Cabot first reported a position in PFE in Q1 2014 and has held it in 49 quarters since. The position peaked at $31.5M in Q3 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Moors & Cabot held 294,767 shares of Pfizer worth $8.28M as of Q1 2026.
  • Moors & Cabot bought 12,344 Pfizer shares in Q1 2026, an estimated $329K.
  • Pfizer made up 0.35% of Moors & Cabot's portfolio in Q1 2026, its #53 holding.
  • Moors & Cabot first reported a position in Pfizer in Q1 2014 and has held it in 49 quarters since.
  • Moors & Cabot's Pfizer position peaked at $31.5M in Q3 2021.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.